- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Business Performance:** Aurobindo Pharma delivered a robust Q3FY26, with revenue up 8.4% YoY to ₹8,646 Cr. EBITDA grew 9.0% YoY to ₹1,773 Cr (20.5% margin), and Net Profit rose 7.6% YoY to ₹910 Cr. Growth was primarily fueled by strong performance in Europe (+27.4% YoY) and steady US market results, despite lower transient product sales. The ARV business also saw significant growth of 22.4% YoY.
**Growth Drivers or Strategy:** The company is aggressively building its biosimilars pipeline, with two programs in Phase 3 trials and plans to file Denosumab (BP16) and Omalizumab (BP11) biosimilars in the EU and US in 2026. Strategic expansion into global growth markets like Europe (recent launches in UK, Lithuania) and LATAM (Mexico tender listings, Brazil filings) is a key focus.
**Recent Developments:** In the US market, 7 products received approvals and 9 were launched during the quarter. The company generated strong free cash flows of $118 million, ending with a net cash position (including investments) of approximately US$ 251 million post-acquisition. R&D spend was ₹409 Cr, mainly for biosimilars and specialty products.
**Key Financial Metrics:**
* Revenue: ₹8,646 Cr (+8.4% YoY)
* EBITDA: ₹1,773 Cr (+9.0% YoY)
* Net Profit: ₹910 Cr (+7.6% YoY)
* EPS: ₹15.67 (+7.7% YoY)
**Management Commentary / Outlook:** Management highlights continued launch momentum in Europe and Canada, with further approvals expected in 2026. The biosimilars pipeline remains strong with 8 early-stage candidates targeting a market opportunity exceeding $50 billion by 2032. Pre-submission meetings for their bevacizumab biosimilar in the US are underway for a targeted filing in Q2/Q3 CY2026.